Results 21 to 30 of about 69,283 (286)
Why humans need type 5 phosphodiesterase inhibitors [PDF]
International Journal of Andrology, 2005 SummaryErectile dysfunction (ED) is a widespread medical condition affecting millions of males at any age and requiring medical treatment. ED may simply reflect a limit of human physiology, yet ED equates to genetic death and the high prevalence of ED is a clear evolutionary paradox.
CELLERINO, Alessandro, JANNINI E. A.
openaire +3 more sources
Toxins, 2023 Intracavernosal injections of botulinum toxin A (BTX/A ic) may be effective for difficult-to-treat erectile dysfunction (ED). This is a retrospective case series study of the effectiveness of repeated off-label BTX/A ic (onabotulinumtoxinA 100U ...
François Giuliano +2 more
doaj +1 more source
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +1 more source
Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2009 ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos +3 more
openaire +4 more sources
The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]
, 2017 Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Barrick, TR +6 more
core +1 more source
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Journal of Microscopy and Ultrastructure, 2020 COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension;
Al-Kuraishy, Hayder M. +5 more
openaire +3 more sources
Phosphodiesterase type 5 Inhibitors (PDE-5I) as a potential therapeutic drug in stroke: A systematic narrative review [PDF]
Romanian Journal of Neurology, 2023 Objectives. Stroke is an acute cerebrovascular disease with high morbidity and mortality rate. Many stroke management strategies can improve prognosis and quality of life, but only to a certain extent.
Harvey Sudharta +5 more
doaj +1 more source
Management of erectile dysfunction post-radical prostatectomy [PDF]
, 2014 © 2015 Saleh et al.Radical prostatectomy is a commonly performed procedure for the treatment of localized prostate cancer. One of the long-term complications is erectile dysfunction.
Abboudi, H +4 more
core +1 more source
Erectile dysfunction in diabetes mellitus: A review
Journal of Diabetology, 2020 The International Diabetes Federation estimates that globally there are 425 million people with diabetes. Estimates of the prevalence of erectile dysfunction (ED) in men with diabetes range from 20% to 85% in different studies.
Deepak K Jumani, Omkar Patil
doaj +1 more source
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]
, 2016 Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S. +4 more
core +1 more source